Stocks · News reference
Psyence Biomedical Ltd. has finalized a $2,599,896 investment in Psyence Labs Ltd. after achieving key regulatory and manufacturing milestones for its ibogaine program.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today announced that both milestones attached to its backstop subscription commitment in Psyence Labs Ltd. ("PsyLabs")
Benuvia operates an 83,000-square-foot, DEA-registered controlled-substance manufacturing facility in Round Rock, Texas, with capabilities spanning development through commercial-scale productionPartnership is intended
The term sheet is binding on the parties and is to be superseded by a definitive agreement, which the parties have agreed to conclude on or before November 30, 2026; if a definitive agreement is not signed by that date,